A Study About Fazirsiran in People With and Without Liver Problems
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
The main aim of this study is to learn how the body processes fazirsiran (pharmacokinetics
[PK]) in people with mild, moderate, or severe liver problems, compared to people with normal
liver function.
The study will include participants with liver scarring (cirrhosis) and mild, moderate, or
severe liver problems, and participants with normal liver function. All participants will be
given 1 injection of fazirsiran and will be followed up for 6 months after the fazirsiran
injection.